Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study for Use of Oral Fludarabine Plus Cyclophosphamide and Rituximab Followed by Zevalin as Front-Line Treatment for Non-Follicular Indolent Lymphomas.

NCT00354822 is registered in ClinicalTrials.gov with A.O. Ospedale Papa Giovanni XXIII as lead sponsor.

NCT NCT00354822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00354822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study for Use of Oral Fludarabine Plus Cyclophosphamide and Rituximab Followed by Zevalin as Front-Line Treatment for Non-Follicular Indolent Lymphomas.
Lead sponsor
A.O. Ospedale Papa Giovanni XXIII
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2005
Completion date
August 31, 2009
Enrollment
25 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin